To assess the potential contribution of the cysteine-rich domain of human platelet glycoprotein (GP) llla to the structure of the PIA' epitope, we used site-directed mutagenesis to substitute alanines for cysteines at key positions potentially involved in PIA' alloantigen formation. One of these GPllla isoforms in which alanine replaced Cysus reacted normally with a series of well-characterized murine MoAbs directed against the 250 amino-terminal residues of GPllla, whereas binding of MoAbs specific for residues 348-692 was diminished or lost. Interestingly, of eight PIA'-specific antibodies tested, two recognized AlaU,GPllla, two did not, and four bound to it less well than to wild-type (W) GPllla. However, disruption of disulfide bonds located at or near the N-termi-HE PLA'/PLA* (also known as the HPA-1) alloantigen system is most frequently responsible for eliciting an immune response in both posttransfusion purpura (PTP) and neonatal alloimmune thrombocytopenic purpura (NATP). Accordingly, considerable attention has been directed to resolve the exact molecular structure of these di-allelically inherited antigenic determinants. First localized to platelet membrane glycoprotein (GP) IIIa by Kunicki and Aster' in the late 1970's, the PIA' alloantigen was later found to reside on a 17-kD noncarbohydrate region of the molecule.* The expression of the PIA' and PIA2 antigens is now known to be controlled by a point mutation at GPIIIa nucleotide 196,' resulting in a Leu33Pro substitution within a small 13 amino acid disulfide-bonded loop at the amino terminal region of GPIIIa. Whereas a leucine at position 33 leads to the formation of the PIA' epitope, proline 33 controls expression of Although the polymorphic amino acid residues that control the formation of the clinically important platelet alloanti- Hematology, December 3-7, 1993, St Louis, MO and 
nus of GPllla abolished the binding of all the anti-PIA' alloantibodies tested. These findings provide evidence that the humoral response to the PIA' antigen is (1) heterogenous, ie, the binding site on GPllla for human anti-PIA' antibodies differs from one individual to another and (2) complexalthough some anti-PIA1 alloantibodies bind to an epitope comprised solely of the amino-terminus of GPllla, others combine most efficiently with a more complex determinant that involves the cysteine-rich domain of GPllla. These findings may have implications for diagnostic and therapeutic use of synthetic or recombinant PI"' mimetics. 0 1995 by The American Society of Hematology.
genic determinants, including PIA', are now known,'.' the actual antibody combining sites on the target glycoproteins have not been precisely identified yet. It is possible, and in most instances likely, that the polymorphic amino acids themselves constitute at least part of the epitope. However, other linearly distant, conformationally close regions of the polypeptide chain may help to stabilize the conformation recognized by alloantibodies and may additionally form a necessary part of the antibody binding site. It has been known for some time that the PIA' antigen is sensitive to disulfide bond reduction'.* and several groups have shown that the amino terminal region of GPIIIa, which contains the PIA polymorphism is itself cysteine-rich and is linked to the cysteine-rich core of the glycoprotein by the disulfide bond between cysteines 5 and 435,7 resulting in the formation of' a large loop structure.*-" ' To better define the structures involved in anti-PIA' alloantibody binding to the GPIIIa molecule. a number of laboratories have attempted to produce recombinant fragments or synthetic peptides that mimic the antigens recognized by alloantibodies. The failure to mimic the PIA' epitope using small linear'' or cyclic (P.J. Newman, T.J. Kunicki, and N. Valentin, unpublished observations, July 1990) synthetic peptides encompassing amino acid 33 reinforced the concept that the PIA' antigenic determinant may require regions of the polypeptide chain distal to polymorphic residue 33. Some degree of Pl"' antigenic activity does appear to reside in a minimal 66 residue amino-terminal recombinant fragment of GPIIIa,"~" but the relative affinities of anti-PIA' alloantibodies for these small GPIIIa fragments have not yet been examined. To assess the potential contribution of the cysteinerich core of GPIIIa to the PIA' antigenic determinant, we took the approach of disrupting the CysS-CysJis disulfide bridge that links these two regions of the m o l e c~l e .~ Our results indicate that (1) all anti-PIA' antibodies are not alike, and (2) the majority of anti-PlA' antibodies interact optimally with a complex combinatorial determinant, the expression of which requires or is stabilized by the C-terminal cysteinerich domain of GPIIIa. (14) (N. Valentin, unpub., 3/92)' (18) * The specificity of these antibodies has been described in abstract form only.
MATERIALS AND METHODS
Antibodies. The GPIIIa-specific murine monoclonal antibodies (MoAbs) AP3,I4 AP5, and AP615.16 were produced and characterized at the Blood Center of Southeastern Wisconsin (BCSEW; Milwaukee, WI). AP5 and AP6 were kindly provided by Dr Thomas J. Kunicki (Scripps Research Institute, La Jolla, CA). The MoAb NaM7D6, which recognizes the cysteine-rich region of GPIIIa, was a generous gift of Dr Dominique Blanchard (Blood Center, Nantes, France). The MoAbs CRC54," SZ21," and LK4," directed against GPIIIa were graciously provided by Drs Alexey Mazurov (Institute of Experimental Cardiology, Moscow, Russia), Changgeng Ruan (Suzhou Medical College, Jiangsu, China), and Simon Karpatkin (New York University Medical School, New York, NY), respectively. Eight anti-PIA' alloantibodies derived from individuals with PTP (numbered 1 to 4) and NATP (numbered 5 to 8) were provided by the Clinical Platelet Antibody Laboratory of the BCSEW and used as unpurified sera to avoid biasing their original specificity. Table 1 summarizes the epitope locations of the MoAbs used in this study.
Site-directed mutagenesis of GPIIIa cDNA. The full-length cDNA of the wild-type (WT) form of GPIIIa, containing a silent mutation to remove the internal EcoRI site at base 2274 (gift of Dr Gilbert C. White II, University of North Carolina, Chapel Hill, NC), was cloned into EcoRI site of plasmid vector pGE"7zf(+) (Promega, Madison WI). The transformer site-directed mutagenesis kit (Clontech, Palo Alto, CA) was used with a single-base mismatched oligonucleotide as the selection primer (S'ATGCTCCTCTC GACT-CGAGG3'). deleting a unique Xba I restriction site in pGEM-7zf(+) to allow positive selection of the mutants. To obtain the double alanine mutants, two primers containing two mismatches each were annealed simultaneously to the vector: 5'-GGGCCCAACATCGC TACCACGCGAGG-3' for Ala at position 5 and 5'"ITTGA-T-TGTGACGCTGCCTGCCAGGC-3' for Ala at position 435, 5'-GTGTGCCTGGGCCTCTG-ATGAG-3' for Ala 26 and 5'-CTCACCTGCGCTGACCTGAAG-3' for Ala 38, and finally 5'-TGAGCCCCATGGCTGCCTGGTGC-3' for Ala 23 of GPIIIa.
After mutagenesis, cDNAs were shuttled from pGEM-7 to the mammalian expression vector pcDNA3 (Invitrogen Corp, San Diego, CA) for expression in COS-7 cells. Duplicate cDNA constructs for each mutant glycoprotein were used for transfection analysis to ensure reproducibility. The double mutant Ala5.Ala435 cDNA was also used for construction of single cysteine+alanine mutant forms of GPIIIa by swapping 5' fragments of GPIIIa cDNA generated by digestion with either BstBI (Ala,GPIIIa) or Kpn I (Alq&PIIIa). DNA fragments were then gel-purified and ligated back into pcDNA3. All constructs derived by site-directed mutagenesis were analyzed using either automated (Applied Biosystems, Foster City, CA) or manual (Sequenase 2.0, US Biochemical Corp, Cleveland, OH) sequencing.
Transfection and analysis of recombinant GPIIIa mutants in COS-7 cells. COS-7 cells (American Type Culture Collection, Rockville, MD) were grown and transfected as previously described?' Briefly, cells plated 16 hours before transfection at 1 X 106cells/10sm plate in Dulbecco's modified Eagle's Media (DMEM) (Life Technologies, Inc, Gaithersburg, MD) containing 2 mmoVL glutamine and 10% fetal calf serum were transfected according to the DEAE-Dextran method" with 1.5 pg of wild-type or mutant GPIIIacDNNpcDNA3 constructs. Two days after transfection, cells were depleted of methionine and labeled with 400 pCi of %-methionine (DuPont-NEN, Boston, MA) per plate for 4 hours at 37" C. Labeled cells were washed in PBS containing 1 mg/mL cold methionine, and then solubilized in 1 mL of lysis buffer (50 mmol/L TRIS-HC1, 150 mmoV L NaCl, pH 7.4 containing 1% Triton X-100, 2 mmoVL phenylmethylsulfonyl fluoride and 10 mmol/L N-ethylmaleimide for 30 minutes on ice. F'reclearing and immunoprecipitation were performed as previously described:' with minor modifications. Briefly, detergent lysates were centrifuged, precleared with 10 pg of normal mouse IgG (for murine monoclonal immunoprecipitations), 25 pg of normal rabbit IgG (for polyclonal rabbit immunoprecipitations), or 50 pL of normal human serum (for human alloantibody immunoprecipitations) in the presence of 25 pL of packed protein A-sepharose beads and 10% bovine serum albumin (BSA) (Sigma Chemical CO, St Louis, MO) for 1 hour at room temperature (RT). After centrifugation at 6,OOOg for 5 minutes, precleared supernatants were incubated with 10 pg of MoAb, 25 pg of polyclonal antibody, or 50 pL of human alloantibody for 16 hours at 4°C on a nutator. Ten micrograms of rabbit antimouse Ig (Dako Corp, Carpenteria, CA) were added to all IgGl monoclonal immunoprecipitations for 1 hour before addition of protein A-sepharose. The beads were washed exhaustively and immune complexes were eluted under reducing conditions and run on a 7% sodium dodecyl sulfate (SDS)-polyacrylamide gel. The gel was fixed and soaked in Enlightening solution (DuPont NEN) for 30 minutes, dried and exposed against film (Kodak XRP) for 2 to 24 hours at -80°C.
Competitive enzyme-linked immunosorbent assay. Fifty microliters of a 2-pg/mL solution of Concanavilin A-purified GPIIb-IIIa was immobilized in Easywash Coming microtiter wells and used for the immunocapture of biotiny-lated anti-PIA' IgG no. 1 (see Results) in the presence or absence of (1) blocking murine MoAbs or (2) human alloantisera, using methods previosly described by Visentin et al."
RESULTS

The amino terminus of GPIIIa and other related integrin
p subunits is extremely cysteine-rich, containing seven cysteine residues within the first 49 amino acid residues.23*" One of these, Cys 5, is thought to be paired with cysteine 435 within the cysteine-rich domain of the molecule,' thus bringing these two regions into close physical proximity. To examine the contribution of the C-terminal cysteine-rich domain of GPIIIa to the expression of the PIA' alloantigenic determinant, we constructed a series of mutant forms of GPIIIa in which alanines were substituted for cysteine residues, alone or in pairs.
After their expression in COS-7 fibroblasts, a series of polyclonal and well-characterized MoAbs were then used to determine the effects of these mutations on the conformation of the mutant glycoproteins. One of these isofonns, Cys,,pAla, was characterized in For personal use only. on October 3, 2017. by guest www.bloodjournal.org From some detail because, in theory, it should have a minimal effect on the expression of epitopes that require only an intact amino terminus for their formation and expression. As shown in Fig I , substitution of Ala for Cys at position 435 had little or no effect on the binding of AP5, SZ21, LK4, CRC54, or AP6 of which antigenic determinants have been previously localized to distinct regions along the first 250 amino-terminal residues of GPIlIa. In contrast, substitution of Cys 435 resulted in the loss of epitopes for antibodies that bind at or near the cysteine-rich domain of GPIIIa, as indicated by the loss of binding of AP3 and 7D6.
In light of the ability of the Alass form of GPIlIa to discriminate between antibodies that bind at or near the amino-terminus from those that require a proximal cysteinerich domain, we next examined the ability of several human anti-PI"' alloantibodies to react with this GPIIIa isoform. Specifically, we wished to determine whether anti-PI"' alloantibodies would behave like amino-terminal-specific antibodies, or like antibodies that required residues proximal to Cysdss for their binding. We hypothesized that if the antibody-combining site on GPIIIa for anti-PI"' alloantibodies requires the cysteine-rich domain, then the Cys33s Ala mutation might affect their binding. Conversely, if anti-PI"' antibodies bind only at or near polymorphic residue 33, then a local amino acid substitution at residue 435 should not affect their binding. As shown in Fig 2, when eight different anti-PI"' antibodies (four PTP and four NATP) were examined for their ability to immunoprecipitate Alai35GPllla, two of them (numbers 1 and 5; lane b) were completely unreactive and four retained some reactivity (nos. 2, 6, 7, and 8; lane b), whereas two others had no loss of binding at all (numbers 3 and 4; lane b) compared with wild-type recombinant GPIIIa (all nos.; lane c). Thus, it would appear that the alloimmune response to the PI" polymorphism varies from individual to individual. Although some individuals produce anti-PI"' alloantibodies that bind to an epitope comprised solely of the amino-terminal 66 amino acid residues of GPII~a ' l . ' 3 (Fig 2, sera nos. 3 and 4) , others respond to the polymorphism at residue 33 by producing alloantibodies that recognize a more complex determinant that involves the cysteine-rich domain (Fig 2, seras I , 2, 5, 6, 7, and 8) . Importantly, no correlation appears to exist between the complexity of the epitope recognized and the source (NATP 17 PTP) of the alloimmune sera.
Though anti-PI"' antibodies were found to vary in their reactivity with the GPIIIa isoform harboring a mutation within the cysteine-rich domain, all appear to have an absolute requirement for an amino terminus having an intact disulfide bond structure. As shown in Fig 3 , when anti-PI"' antibodies derived from alloimmunized individuals no. I and 4, which represented the two extremes of reactivity with the form of GPIlIa (see Fig 2) . were examined for their ability to react with GPIIla molecules containing cysteine to alanine mutations at residues 5,23,26, or 38, all PI"' reactivity was lost. Thus, despite a differential requirement for contribution of the cysteine-rich domain, the PI"' alloanti- For personal use only. on October 3, 2017. by guest www.bloodjournal.org From ..
SDS-PAGE under reducing conditions, as expected.
." genic determinant is invariant in its requirement for a conformationally correct amino-terminus. The amino terminal contribution to the binding site recognized by all anti-PI"' alloantibodies was further reinforced by a series of competition experiments shown in Fig 4 in which ( l ) MoAbs directed against the first 1 0 0 amino acids of GPIIIa were found to be equally effective in blocking the binding of anti-PI"' antibodies from alloimmunized individuals no. 1 and 4 to purified platelet GPIlb-IIla (Fig 4A) , and ( 2 ) binding to purified platelet GPIIb-IIIa of affinity purified anti-PI"' IgG from alloimmunized individual no. 1 was inhibited effectively by all anti-PI"' alloantisera tested, regardless of their ability to react with the mutant form of GPIIIa (Fig 4B) . Taken together, these data strongly suggest that all anti-PI"' alloantibodies bind at or near amino acid 33, but approach the polymorphic residue from a different orientation relative to the cysteine-rich domain of GPllla.
DISCUSSION
The purpose of the present investigation was to further characterize the structural requirements for the formation and stable expression of the human platelet alloantigen, PI"'. Using a series of cysteine to alanine mutations, we attempted to produce recombinant GPllla molecules that differed in their ability to react with human anti-PI"' antibodies. One GPlIIa isoform, Ala,3sGPIIIa, was particularly informative in that it was found to react efficiently with anti-PI"' alloantibodies produced by some, but not all, individuals. On the basis of these findings, it appears that the way in which human anti-PI"' antibodies interact with GPIIIa differs from one alloimmunized individual to another. Whereas some anti-PI"' antibodies (eg. sera nos. 3 and 4 of Fig 2 and those likely used in references 12 and 13, hereafter referred to as type I anti-PI"' alloantibodies) bind at or near the Leu33/Pro33 polymorphic amino acid residue without the requirement for distal regions of the GPIlIa polypeptide chain. others (type I1 antibodies) react with the amino-terminus only when it is in close apposition to the cysteine-rich core (residues 433-692). In the latter case, the antibody recognition site on GPllla is likely to be combinatorial in nature. In this regard, it is of interest that the reactivity for GPIIla of anti-PI"' alloantisera nos. 1 and 5 (Fig 2 ) was completely, and not partially, abolished by substitution of an alanine for Cys 435. These data suggest that the humoral response to the PI"' epitope in some instances is highly restricted, or even monospecific in nature-ie, individuals may produce either type I or I1 antiP1"' antibodies, but not both.
The fact that type I and I1 antiP1"' alloantibodies have different structural requirements for binding implies that they recognize GPllla in different orientations relative to the Leu3JPro33 polymorphic site. However, these epitopes, though different, would appear to be in close proximity with one another because ( 1 ) both type I and I1 antibodies require an intact amino terminus of the GPlIIa molecule (Fig 3 ) , ( 2 ) binding of both type I and I1 anti-PI"' antibodies to GPlIIa is inhibited by MoAbs SZ21 and LK4 (Fig 4A) , both of which are known to bind to GPIIIa at or near the PI"' antigenic and (3) type l and I1 anti-PI"' antibodies compete with each other for binding to both intact platelets or purified GPIIb-IIIa (Fig 4B) . Thus, all anti-PI"' alloantibodies likely bind at or near amino acid 33, but approach the polymorphic residue from a different aspect or perspective. These findings may have important implications for diagnostic and therapeutic use of synthetic or recombinant PI"' mimetics."."
Previous investigators have suggested that all anti-PI"' alloantibodies may not be alike. Cines and Schreibe?' studied the interaction of complement with human platelets pretreated with anti-PI"' antibodies and found efficient platelet lysis and serotonin release in all antisera they studied, but several groups have reported noncomplement fixing anti-PI"' antibodies in NATP sera or in convalescent plasma.'"'" Because of the different way in which they interact with GPIIIa on the platelet surface, it is conceivable that type I and as described above and incubated with saturating levels (determined experimentally) of the indicated anti-PIA' alloantisera. Binding of blocking anti-PIA' IgG (black histograms) was determined by subsequent addition of biotinylated HB43, a murine antihuman IgG MoAb. In parallel wells, affinity-purified, biotinylated anti-PI"' IgG from alloimmunized individual no. 1 (dotted histogram) was added instead of HB43. Controls included prior incubation with normal human serum (NS), which had no effect on the binding of anti-PIA' no. 1, and unlabeled serum no. 1, which blocked itself. Note that all PIA' antisera tested effectively inhibited binding of biotinylated anti-PIA' IgG no. 1, regardless of their ability t o react with the AlauS form of GPllla. NATP-and PTP-derived anti-PIA' were equally effective competitive inhibitors, as shown. Identical results were obtained in a flow cytometric competition assay using intact platelets (not shown).
I1 antibodies may differ in their ability to fix complement or inhibit platelet aggregation.."'.'' Therefore. it is possible that a relationship exists between the nature of the epitope recognized and the severity of thrombocytopenia and/or intracranial hemorrhage that currently occurs unpredictably in cases of NATP. Further studies to examine the way in which type I and 11 anti-PI"' antibodies interact with the GPIIIa polypeptide chain will be required to understand fully the potential clinical implications of these findings.
Finally. NATP and PTP are among the most tightly MHCassociated diseases in man. Studies performed within the past S years have shown that all the individuals who produce anti-PI"' alloantibodies that result in NATP or PTP are not only PI"' homozygous. but also express the DRS2 class 11 molecule.32.23 Most frequently, individuals responding to the PI"' alloantigen are DRS2a positive.'" but DRS2b and DRS2c PI"' homozygous individuals have also been shown to produce anti-PI"' antibodies'5 (Dr J. Gorski. The Blood Center of Southeastern Wisconsin. personal communication.
September 1991). Because naive B-cells that express surface Ig having type I versus type I1 anti-PI"' specificity may differ in the way in which they bind GPIIIa. it is possible that GPllla is processed differently, resulting in the generation of peptides that interact preferentially with DRS2a. DRS2b. or DRS2c molecules. For instance, B-cells expressing type I anti-PI"' Ig may generate peptides that bind DRS2a molecules efficiently, but that interact with DRS2b and DRS2c molecules poorly, whereas type I1 anti-PI"' Ig may bind GPIlIa in such a way as to result in the generation of peptides that are antigenic only in the context of DRS2b or c. but not DRS2a. The precise relationships of antigen presentation. MHC restriction, and T-cell recognition that underly the immunogenicity of the alloimmune response to PI"' remains an intruiging avenue of future investigation.
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